Evidence map›Paper›PMID 31727007›Full record

ArticleBMC ophthalmology2019

Serum erythropoietin concentration and its correlation with stage of diabetic retinopathy.

Sofija Davidović, Nikola Babić, Sandra Jovanović, Sava Barišić, Desanka Grković, Aleksandar Miljković

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Systemic and vitreous biomarkers - new insights in diabetic retinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Observational
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sofija DavidovićFaculty of Medicine, Department of Ophthalmology, University of Novi Sad, Novi Sad, 21000, Serbia. SOFIJA.DAVIDOVIC@mf.uns.ac.rs.ORCID http://orcid.org/0000-0002-7597-0437
Nikola BabićFaculty of Medicine, Department of Ophthalmology, University of Novi Sad, Novi Sad, 21000, Serbia.
Sandra JovanovićFaculty of Medicine, Department of Ophthalmology, University of Novi Sad, Novi Sad, 21000, Serbia.
Sava BarišićEye Clinic, Clinical Center of Vojvodina, Hajduk Veljkova 1-9, Novi Sad, 21000, Serbia.
Desanka GrkovićFaculty of Medicine, Department of Ophthalmology, University of Novi Sad, Novi Sad, 21000, Serbia.
Aleksandar MiljkovićFaculty of Medicine, Department of Ophthalmology, University of Novi Sad, Novi Sad, 21000, Serbia.
University of Novi Sad · RSKlinički centar Vojvodine · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis and in diabetic retinopathy (DR) is not yet fully understood. The latest research data reveal a possible correlation of higher erythropoietin concentrations in the blood and in the eye with the development of more advanced stages of DR. The main aim of this work was to examine the possible influence of serum concentrations of erythropoietin on the development of diabetic retinopathy in patients with diabetes mellitus type 2.

methodsThe research involved 90 patients examined at the University Eye Clinic of the Clinical Center of Vojvodina, Novi Sad, Serbia. The first group comprised 60 patients with diabetes mellitus lasting for 10 years or more, with diabetic retinopathy. The second, control group consisted of 30 healthy individuals. In the first group of 60 patients with diabetes, 30 of them had non-proliferative diabetic retinopathy (NPDR), and 30 had proliferative diabetic retinopathy (PDR). Laboratory EPO serum levels were determined, and they were correlated to the stage of DR. Concentration of EPO was assessed by ELISA method.

resultsThe highest average concentration of EPO in serum (9.95 mIU/ml) was determined in the group of people with diabetes with PDR. The lowest average concentration of EPO in the serum (6.90 mIU/ml) was found in the control group. The average concentration of EPO in serum in the group of patients with diabetes with NPDR was 7.00 mIU/ml. The EPO concentration in serum was elevated in the group of PDR, and it was directly proportional to the level of the clinical stadium of PDR, being significantly higher in the moderate and severe subgroup of PDR comparing to the control healthy subjects, NPDR and mild PDR (p = 0.007).

conclusionsSignificantly elevated serum concentration of EPO in the advanced stages of DR, and positive correlation between EPO serum concentration and clinical stages of PDR, suggest that erythropoietin represents an important growth factor from blood, which plays a significant role in retinal ischemia and angiogenesis in diabetic retinopathy, especially in the proliferative stage of this disease.

Indexed as

AgedAged, 80 and overCase-Control StudiesCross-Sectional StudiesDiabetes Mellitus, Type 2Diabetic RetinopathyErythropoietinFemaleGlycated HemoglobinHumansIntraocular PressureMaleMiddle AgedVisual AcuityEPO protein, humanErythropoietinGlycated Hemoglobinhemoglobin A1c protein, humanDiabetic retinopathyErythropoietinGrowth factors

Identifiers

PMID31727007
PMCPMC6857223
OpenAlexW2985445693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.